Allen Holding Inc. NY Purchases 480,200 Shares of Pfizer Inc. $PFE

Key Points

• Allen Holding Inc. NY increased its Pfizer stake by 31.6% in the first quarter, buying 480,200 additional shares and bringing its total to 2.0 million shares worth about $56.2 million.
• Institutional ownership remains strong, with hedge funds and other investors holding 68.36% of Pfizer’s shares overall.
• Wall Street sentiment is cautious: Pfizer currently has a Hold consensus rating and an average price target of $28.50, while analysts have recently trimmed some targets and ratings.

Allen Holding Inc. NY grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 31.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,000,000 shares of the biopharmaceutical company's stock after buying an additional 480,200 shares during the quarter. Pfizer makes up about 5.6% of Allen Holding Inc. NY's investment portfolio, making the stock its 4th biggest position. Allen Holding Inc. NY's holdings in Pfizer were worth $56,160,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Commonwealth Financial Services LLC raised its stake in shares of Pfizer by 9.5% in the first quarter. Commonwealth Financial Services LLC now owns 42,617 shares of the biopharmaceutical company's stock worth $1,197,000 after acquiring an additional 3,690 shares during the last quarter. Meeder Asset Management Inc. grew its stake in shares of Pfizer by 130.9% during the first quarter. Meeder Asset Management Inc. now owns 2,789 shares of the biopharmaceutical company's stock valued at $78,000 after purchasing an additional 1,581 shares during the last quarter. Meeder Advisory Services Inc. grew its stake in shares of Pfizer by 18.0% during the first quarter. Meeder Advisory Services Inc. now owns 116,700 shares of the biopharmaceutical company's stock valued at $3,277,000 after purchasing an additional 17,764 shares during the last quarter. Lowe Brockenbrough & Co. Inc. increased its holdings in shares of Pfizer by 13.9% in the first quarter. Lowe Brockenbrough & Co. Inc. now owns 238,855 shares of the biopharmaceutical company's stock valued at $6,707,000 after purchasing an additional 29,130 shares in the last quarter. Finally, Symphony Financial Services Inc. raised its position in Pfizer by 4.9% in the 1st quarter. Symphony Financial Services Inc. now owns 24,645 shares of the biopharmaceutical company's stock worth $692,000 after purchasing an additional 1,148 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. JPMorgan Chase & Co. dropped their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Wednesday, July 8th. Guggenheim cut their price target on Pfizer from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Monday, July 13th. Bank of America decreased their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. Finally, Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research report on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $28.50.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent commentary continues to focus on Pfizer’s pipeline potential, with articles asking whether the company can strengthen its growth story through new drug development and recent approvals, which could support a longer-term rebound. Can Pfizer NYSE: PFE Strengthen Its Pipeline Story?
• Positive Sentiment: Pfizer remains attractive to income-focused investors, with coverage highlighting it as a high-yield dividend stock and a potential “buy on the dip” name, which may help limit downside. 3 High-Yield Dividend Stocks to Buy and Hold
• Neutral Sentiment: Analysts are still modeling solid full-year earnings, but Erste Group slightly trimmed its FY2026 EPS estimate for Pfizer to $2.92 from $2.95, signaling only a small downward revision versus the consensus of $2.96.
• Neutral Sentiment: Another valuation-focused note said Pfizer looks “fairly priced” given mixed pipeline risks, suggesting the stock may not be obviously cheap despite its lower valuation and high dividend.
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India because of supply challenges, adding another operational headwind for the company. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines, keeping legal risk and potential costs in focus for PFE. Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech...

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.08 on Monday. The firm has a fifty day moving average of $25.21 and a two-hundred day moving average of $26.18. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a market capitalization of $142.94 billion, a price-to-earnings ratio of 19.15 and a beta of 0.35. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts' expectations of $13.84 billion. During the same period in the previous year, the firm earned $0.92 earnings per share. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer's dividend payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.